Back to search

Peptide record

TPDB05037

RGD-La Antibacterial Anticancer Toxicity Tumor-homing Peptides standard
16 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB05037
RGD-La
Antibacterial Anticancer Toxicity Tumor-homing Peptides
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab TumorHoPe2.0
standard
No
A 16-aa standard natural multi-activity (Antibacterial, Anticancer, Toxicity, and other sources) peptide sequence curated from AntiBP3, Peptipedia, ACP740 _ACP240, and other sources, with an available 3D structural model.
Sequence
RGDLLRHVVKILEKYL
Physicochemical Analysis
C90H154N26O22
ANCQMFPSTW
L
1952.37
10.19
5
2
8
+2
4.47
-0.037
158.12
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
1490
76.32
1
Residue Composition
number
0
A
2
R
0
N
1
D
0
C
1
E
0
Q
1
G
1
H
1
I
4
L
2
K
0
M
0
F
0
P
0
S
0
T
0
W
1
Y
2
V
Amino Acid Distribution
A: 0 R: 2 N: 0 D: 1 C: 0 E: 1 Q: 0 G: 1 H: 1 I: 1 L: 4 K: 2 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 2
Chemical Descriptors
16
C90H154N26O22
1952.37
10.19
+2
4.47
-0.037
Free
L
Linear
Free
Anticancer
Arg-Gly-Asp(RGD) tripeptide ana temporins Arg-Gly-Asp(RGD) tripeptide aNot Available temporins
Evidence Records 14 records
Evidence 1 Activity

Activity

72.69 Inhibition ratio at 50 µg/ml
Anticancer

Target

Colorectal Cancer
SW-1116
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

70.39 Inhibition ratio at 50 µg/ml
Anticancer

Target

Liver Cancer
SMMC-7721
Liver

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 3 Activity

Activity

73.09 Inhibition ratio at 50 µg/ml
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 4 Activity

Activity

60.22 Inhibition ratio at 50 µg/ml
Anticancer

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 5 Activity

Activity

62.49 Inhibition ratio at 50 µg/ml
Anticancer

Target

Gastric Cancer
BGC-823
Stomach

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 6 Activity

Activity

47.26Inhibition ratio at 50 µg/ml
Anticancer

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 7 Activity

Activity

36.25 Inhibition ratio at 50 µg/ml
Anticancer

Target

Liver Cancer
HL7702
Liver

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 8 Activity

Activity

27.86 Inhibition ratio at 50 µg/ml
Anticancer

Target

Renal Cancer
HEK-293T
Renal

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 9 Activity

Activity

19.76 Inhibition ratio at 50 µg/ml
Anticancer

Target

Breast Cancer
MEC
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 10 Activity

Activity

36.25±5.39% Inhibition
Toxicity
50 µg/mL
Cytotoxic
36.25±5.39% Inhibition | 50 | µg/mL | target cell: Human hepatocyte cells HL-7702 (L02)

Target

Human hepatocyte cells HL-7702 (L02)

Source & Reference

NA
DBAASP
Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012
Evidence 11 Activity

Activity

27.86±4.26% Inhibition
Toxicity
50 µg/mL
Cytotoxic
27.86±4.26% Inhibition | 50 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012
Evidence 12 Activity

Activity

19.76±8.65% Inhibition
Toxicity
50 µg/mL
Cytotoxic
19.76±8.65% Inhibition | 50 | µg/mL | target cell: Bovine mammary epithelial cells

Target

Bovine mammary epithelial cells

Source & Reference

NA
DBAASP
Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012
Evidence 13 Activity

Activity

16.22±3.64% Inhibition
Toxicity
50 µg/mL
Cytotoxic
16.22±3.64% Inhibition | 50 | µg/mL | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012
Evidence 14 Activity

Activity

Toxicity
Hemolytic Cytotoxic
Hemolytic_activity: Showed no hemolytic activity against rabbit erythrocytes and human erythrocytes at 250 µg/ml | Cytotoxicity: Showed little effects on the proliferation of the 293T human embryonic kidney cell line, MECs, and human lymphomonocytes at concentrations of less than 50 µg/ml

Target

erythrocytes

Source & Reference

NA
DRAMP
J Pept Sci. 2012 Jul 18(7):476-86.